## [News](/news "News") Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules. Date Range - Any -In The NewsPress ReleaseFeatured NewsStory News Type Filters Language- Any -EnglishGermanFrench Start Date End Date - [All](#tab-all) - [Press releases](#tab-press-releases) - [Ad hoc releases](#tab-ad-hoc-releases) - [Statements](#tab-statements) - [Stories](#tab-stories) - [ Press release Aug 19, 2026### Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding… ](/news/media-releases/novartis-data-esc-congress-2026-reinforce-cardiovascular-leadership-and-showcase-progress-next-generation-therapies) - [ Press release Jul 31, 2026### FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in… ](/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease) - [ ![Three data and digital research experts working on computers in a Novartis office. Across Novartis R&D, teams are taking advantage of rapid advances in digital technologies to cut the time it takes to discover and develop drugs for patients while further improving on quality, safety, and the patient experience.](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/data-scientists-in-novartis-lab.png.webp?itok=DFYKHP5p "Data scientists in Novartis lab.") Story Jul 28, 2026 Discovery### Smarter decisions at scale: How Novartis is using AI to advance R&D Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients ](/stories/smarter-decisions-scale-how-novartis-using-ai-advance-rd) - [ ![Novartis Culture Leadership Advisory Board](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/novartis-culture-leadership-advisory-board.jpg.webp?itok=7BdYdWhK "Novartis Culture Leadership Advisory Board") Story Jul 27, 2026 People and Culture### Small shifts. Big impact. The leadership choices that matter most in the age of AI There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change. ](/stories/small-shifts-big-impact-leadership-choices-matter-most-age-ai) - [ ![Scientist looking at a test tube with liquid as he holds it in a Novartis lab. Across R&D, our scientists are pushing the boundaries of science to discover and develop breakthrough medicines, moving from molecule to patient with urgency to help people live better, not just longer.](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/scientist-in-novartis-lab.png.webp?itok=ZLhw3z9q "Scientist looking at a test tube with liquid as he holds it in a Novartis lab. Across R&D, our scientists are pushing the boundaries of science to discover and develop breakthrough medicines, moving from molecule to patient with urgency to help people live better, not just longer.") Story Jul 24, 2026 Discovery### How Novartis R&D is advancing the next breakthrough innovations Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation ](/stories/how-novartis-rd-advancing-next-breakthrough-innovations) - [ Ad hoc release Jul 21, 2026### Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… ](/news/media-releases/novartis-verzeichnete-im-zweiten-quartal-umsatzsteigerungen-und-baute-die-pipeline-weiter-aus-prognose-fur-das-geschaftsjahr-bekraftigt) - [ Ad hoc release Jul 21, 2026### Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%… ](/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed) - [ ![Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/novartis-merger-1996-building-letters.jpg.webp?itok=Nc3Ar034 "Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus") Story Jul 17, 2026 People and Culture### Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients. ](/stories/novartis-marks-30-years-breakthroughs-building-250-years-discovery-reimagine-what-medicine-can-do-next) - [ Press release Jul 17, 2026### Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… ](/news/media-releases/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-first-and-only-complement-inhibitor-significantly-slow-kidney-function-decline-primary-igan) - [ Press release Jul 06, 2026### Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis… ](/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients) - [ Press release Jul 02, 2026### Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,… ](/news/media-releases/novartis-receives-european-commission-approval-itvisma-spinal-muscular-atrophy-sma) - [ Press release Jun 12, 2026### Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety… ](/news/media-releases/novartis-remind-data-eaaci-show-rhapsido-potential-first-targeted-therapy-chronic-inducible-urticaria-cindu) - [ Press release Aug 19, 2026### Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio® (inclisiran) vs. bempedoic acid in achieving LDL-C goalsNew AZALEA-TIMI 71 analyses will further characterize the bleeding… ](/news/media-releases/novartis-data-esc-congress-2026-reinforce-cardiovascular-leadership-and-showcase-progress-next-generation-therapies) - [ Press release Jul 31, 2026### FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient populationPSMAddition updated results show Pluvicto reduced risk of progression or death by 33% in… ](/news/media-releases/fda-approves-pluvicto-psma-metastatic-hormone-sensitive-prostate-cancer-mhspc-advancing-potential-new-standard-care-across-metastatic-disease) - [ Ad hoc release Jul 21, 2026### Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… ](/news/media-releases/novartis-verzeichnete-im-zweiten-quartal-umsatzsteigerungen-und-baute-die-pipeline-weiter-aus-prognose-fur-das-geschaftsjahr-bekraftigt) - [ Ad hoc release Jul 21, 2026### Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%… ](/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed) - [ Press release Jul 17, 2026### Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,… ](/news/media-releases/novartis-fabhalta-iptacopan-receives-fda-traditional-approval-first-and-only-complement-inhibitor-significantly-slow-kidney-function-decline-primary-igan) - [ Press release Jul 06, 2026### Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis… ](/news/media-releases/novartis-agrees-acquire-myricx-bio-advancing-next-generation-antibody-drug-conjugate-innovation-novel-nmti-payload-expanding-options-cancer-patients) - [ Press release Jul 02, 2026### Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA) First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,… ](/news/media-releases/novartis-receives-european-commission-approval-itvisma-spinal-muscular-atrophy-sma) - [ Press release Jun 12, 2026### Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety… ](/news/media-releases/novartis-remind-data-eaaci-show-rhapsido-potential-first-targeted-therapy-chronic-inducible-urticaria-cindu) - [ Ad hoc release Jun 11, 2026### Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous… ](/news/media-releases/novartis-delpacibart-braxlosiran-del-brax-phase-iii-study-facioscapulohumeral-muscular-dystrophy-fshd-meets-primary-biomarker-endpoint) - [ Press release Jun 08, 2026### Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED… ](/news/media-releases/novartis-highlight-rhapsido-data-across-multiple-immune-mediated-diseases-eaaci-congress-2026) - [ Press release Jun 04, 2026### Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs… ](/news/media-releases/novartis-igan-data-lancet-show-clinically-meaningful-slowing-kidney-function-decline-vanrafia-over-25-years) - [ Press release Jun 03, 2026### Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,… ](/news/media-releases/novartis-cosentyx-pmr-data-new-england-journal-medicine-showed-sustained-remission-vs-placebo-twice-many-patients) - [ Ad hoc release Jul 21, 2026### Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigt Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den… ](/news/media-releases/novartis-verzeichnete-im-zweiten-quartal-umsatzsteigerungen-und-baute-die-pipeline-weiter-aus-prognose-fur-das-geschaftsjahr-bekraftigt) - [ Ad hoc release Jul 21, 2026### Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%… ](/news/media-releases/novartis-delivered-sales-growth-q2-and-further-advanced-pipeline-full-year-guidance-reaffirmed) - [ Ad hoc release Jun 11, 2026### Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous… ](/news/media-releases/novartis-delpacibart-braxlosiran-del-brax-phase-iii-study-facioscapulohumeral-muscular-dystrophy-fshd-meets-primary-biomarker-endpoint) - [ Ad hoc release Apr 28, 2026### Novartis erzielte im ersten Quartal mit prioritären Marken und Neueinführungen ein starkes Wachstum; Prognose für das Geschäftsjahr 2026 bekräftigt Ad-hoc-Mitteilung gemäss Art. 53 KR Erstes QuartalDer Nettoumsatz ging um –5% (kWk1, –1% USD) zurück, da Wachstumstreiber durch Einbussen durch Generika in den USA mehr als… ](/news/media-releases/novartis-erzielte-im-ersten-quartal-mit-prioritaren-marken-und-neueinfuhrungen-ein-starkes-wachstum-prognose-fur-das-geschaftsjahr-2026-bekraftigt) - [ Ad hoc release Apr 28, 2026### Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed Ad hoc announcement pursuant to Art. 53 LRFirst quarterNet sales declined -5% (cc1, -1% USD), as growth drivers were more than offset by US generic erosionContinued strong performance from priority… ](/news/media-releases/novartis-delivered-strong-growth-priority-brands-and-launches-q1-fy-2026-guidance-reaffirmed) - [ Ad hoc release Feb 04, 2026### Novartis erzielte im Jahr 2025 eine Umsatzsteigerung im hohen einstelligen Prozentbereich, eine Kerngewinnmarge von 40% sowie weitere Fortschritte in der Pipeline Ad-hoc-Mitteilung gemäss Art. 53 KRGeschäftsjahrDer Nettoumsatz wuchs um +8% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +14% (kWk, +12% USD)Das Umsatzwachstum beruhte auf… ](/news/media-releases/novartis-erzielte-im-jahr-2025-eine-umsatzsteigerung-im-hohen-einstelligen-prozentbereich-eine-kerngewinnmarge-von-40-sowie-weitere-fortschritte-der-pipeline) - [ Ad hoc release Feb 04, 2026### Novartis delivered high single-digit sales growth, achieved 40% core margin and further advanced the pipeline in 2025 Ad hoc announcement pursuant to Art. 53 LRFull yearNet sales grew +8% (cc1, +8% USD) with core operating income1 up +14% (cc, +12% USD) Sales growth driven by continued strong performance from… ](/news/media-releases/novartis-delivered-high-single-digit-sales-growth-achieved-40-core-margin-and-further-advanced-pipeline-2025) - [ Ad hoc release Nov 24, 2025### Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA) Ad hoc announcement pursuant to Art. 53 LR Itvisma (onasemnogene abeparvovec-brve) demonstrated improved motor function and stabilization in patients regardless of SMA treatment history in Phase III… ](/news/media-releases/novartis-receives-fda-approval-itvisma-only-gene-replacement-therapy-children-two-years-and-older-teens-and-adults-spinal-muscular-atrophy-sma) - [ Ad hoc release Nov 20, 2025### Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets Ad hoc announcement pursuant to Art. 53 LR Mid-term sales guidance rolled forward to +5-6% cc CAGR for 2025-2030, following upgrade of 2024-2029 guidance to +6% cc1Peak sales guidance upgraded for… ](/news/media-releases/novartis-projects-5-6-cc-sales-cagr-2025-2030-long-term-growth-backed-30-potential-high-value-pipeline-assets) - [ Ad hoc release Oct 28, 2025### Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance Ad hoc announcement pursuant to Art. 53 LRQ3 net sales grew +7% (cc1, +8% USD) and core operating income1 grew +7% (cc, +6% USD) Sales growth was driven by continued strong execution on priority… ](/news/media-releases/novartis-delivers-solid-sales-and-core-operating-income-growth-strong-pipeline-progress-q3-reaffirms-fy-2025-guidance) - [ Ad hoc release Oct 28, 2025### Novartis verzeichnet im dritten Quartal solide Steigerungen beim Umsatz und operativen Kernergebnis sowie starke Fortschritte in der Pipeline; Prognose für das Geschäftsjahr 2025 bestätigt Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im dritten Quartal um +7% (kWk1, +8% USD), das operative Kernergebnis1 verbesserte sich um +7% (kWk, +6% USD)Das Umsatzwachstum beruhte… ](/news/media-releases/novartis-verzeichnet-im-dritten-quartal-solide-steigerungen-beim-umsatz-und-operativen-kernergebnis-sowie-starke-fortschritte-der-pipeline-prognose-fur-das-geschaftsjahr-2025-bestatigt) - [ Ad hoc release Oct 26, 2025### Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline Ad hoc announcement pursuant to Art. 53 LR Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseasesAdvances the… ](/news/media-releases/novartis-agrees-acquire-avidity-biosciences-innovator-rna-therapeutics-strengthening-its-late-stage-neuroscience-pipeline) - [ Statement Apr 24, 2026### Novartis withdraws EMA application for adding new indication for Pluvicto® ](/news/novartis-withdraws-ema-application-adding-new-indication-pluvicto) - [ Statement Sep 29, 2025### Bringing breakthroughs to more patients ](/news/bringing-breakthroughs-more-patients) - [ Statement May 08, 2025### Vas Narasimhan named to 2025 TIME100 Health list ](/news/vas-narasimhan-named-2025-time100-health-list) - [ Statement Apr 25, 2025### Europe talks health sovereignty — now it must deliver ](/news/europe-talks-health-sovereignty-now-it-must-deliver) - [ Statement Aug 15, 2024### Novartis statement on Maximum Fair Price for Entresto ](/news/novartis-statement-maximum-fair-price-entresto) - [ Statement Oct 19, 2023### Violence against innocent people runs counter to our work to improve human health ](/news/violence-against-innocent-people-runs-counter-our-work-improve-human-health) - [ Statement Oct 13, 2023### Novartis condemns the terrorist actions against people in Israel and loss of innocent lives ](/news/novartis-condemns-terrorist-actions-against-people-israel-and-loss-innocent-lives) - [ Statement Sep 19, 2023### Novartis statement on collaboration and license agreement for tislelizumab with BeiGene, Ltd. Novartis and BeiGene, Ltd. have mutually agreed to terminate the collaboration and license agreement for tislelizumab, a humanized IgG4 anti-PD-1 monoclonal antibody. ](/news/novartis-statement-collaboration-and-license-agreement-tislelizumab-beigene-ltd) - [ Statement Sep 13, 2023### Novartis provides support for Moroccan earthquake victims ](/news/novartis-provides-support-moroccan-earthquake-victims) - [ Statement Sep 11, 2023### GT005 (PPY988): Development Program in Geographic Atrophy ](/news/gt005-ppy988-development-program-geographic-atrophy) - [ Statement Sep 01, 2023### Novartis statement on filing of Inflation Reduction Act lawsuit ](/news/novartis-statement-filing-inflation-reduction-act-lawsuit) - [ Statement Aug 29, 2023### Novartis statement about Entresto® (sacubitril/valsartan) selection for Medicare Drug Price Negotiation Program ](/news/novartis-statement-about-entresto-sacubitrilvalsartan-selection-medicare-drug-price-negotiation-program) - [ ![Three data and digital research experts working on computers in a Novartis office. Across Novartis R&D, teams are taking advantage of rapid advances in digital technologies to cut the time it takes to discover and develop drugs for patients while further improving on quality, safety, and the patient experience.](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/data-scientists-in-novartis-lab.png.webp?itok=DFYKHP5p "Data scientists in Novartis lab.") Story Jul 28, 2026 Discovery### Smarter decisions at scale: How Novartis is using AI to advance R&D Novartis R&D is harnessing digital technologies to make smart decisions faster, aiming to reduce the time it takes to bring new options to patients ](/stories/smarter-decisions-scale-how-novartis-using-ai-advance-rd) - [ ![Novartis Culture Leadership Advisory Board](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/novartis-culture-leadership-advisory-board.jpg.webp?itok=7BdYdWhK "Novartis Culture Leadership Advisory Board") Story Jul 27, 2026 People and Culture### Small shifts. Big impact. The leadership choices that matter most in the age of AI There is no shortage of conversation about what AI can do. Every day brings a new headline, a new capability, a new prediction about how work will change. ](/stories/small-shifts-big-impact-leadership-choices-matter-most-age-ai) - [ ![Scientist looking at a test tube with liquid as he holds it in a Novartis lab. Across R&D, our scientists are pushing the boundaries of science to discover and develop breakthrough medicines, moving from molecule to patient with urgency to help people live better, not just longer.](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/scientist-in-novartis-lab.png.webp?itok=ZLhw3z9q "Scientist looking at a test tube with liquid as he holds it in a Novartis lab. Across R&D, our scientists are pushing the boundaries of science to discover and develop breakthrough medicines, moving from molecule to patient with urgency to help people live better, not just longer.") Story Jul 24, 2026 Discovery### How Novartis R&D is advancing the next breakthrough innovations Novartis R&D leaders discuss how Novartis science, technology and strategy are shaping the next decade of innovation ](/stories/how-novartis-rd-advancing-next-breakthrough-innovations) - [ ![Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-07/novartis-merger-1996-building-letters.jpg.webp?itok=Nc3Ar034 "Several people working at assembling the big letters forming "Novartis" that will be installed at the top of a building on the Novartis Basel campus") Story Jul 17, 2026 People and Culture### Novartis marks 30 years of breakthroughs, building on 250 years of discovery to reimagine what medicine can do next The roots of Novartis reach back more than 250 years, to the chemical and scientific traditions that helped shape modern healthcare. Thirty years after its creation, a legacy of discovery and curiosity continues to guide its pursuit of new possibilities for patients. ](/stories/novartis-marks-30-years-breakthroughs-building-250-years-discovery-reimagine-what-medicine-can-do-next) - [ ![3D rendering of a radioligand therapy targeting cancer cells. Novartis is building on its pioneering work developing RLT and other therapeutic technology platforms to design the next wave of prostate cancer treatments.](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-05/3d-rendering-of-a-radioligand-therapy-targeting-cancer-cells.png.webp?itok=Rble1t_U "3D rendering of a radioligand therapy targeting cancer cells. Novartis is building on its pioneering work developing RLT and other therapeutic technology platforms to design the next wave of prostate cancer treatments.") Story May 26, 2026 Discovery### Pushing the prostate cancer treatment frontier: Radioligand therapy and beyond Radioligand therapy (RLT) has helped change what’s possible in prostate cancer treatment, but Novartis continues to work on the next wave of innovations to bring new options to patients. ](/stories/pushing-prostate-cancer-treatment-frontier-radioligand-therapy-and-beyond) - [ ![Novartis partners with Special Olympics World Winter Games Switzerland 2029](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-04/novartis-partners-with-special-olympics-world-winter-games-switzerland-2029-hero.png.webp?itok=LJQAZsNC "Novartis partners with Special Olympics World Winter Games Switzerland 2029") Story May 04, 2026 People and Culture### Novartis partners with Special Olympics World Winter Games Switzerland 2029 Novartis partners with the Special Olympics to support neuro‑inclusion and build environments where everyone belongs. ](/stories/novartis-partners-special-olympics-world-winter-games-switzerland-2029) - [ ![Novartis Pavillon reception with bookshelves and seating area](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-04/novartis-pavillon-reception-with-bookshelves-and-seating-area.png.webp?itok=sZDOnN8- "Novartis Pavillon reception with bookshelves and seating area") Story Apr 28, 2026 People and Culture### Full Circle: A Story of Growth, Purpose and Coming Home to Novartis Polly Cooper, Clinical Development Function Head, UK ](/stories/full-circle-story-growth-purpose-and-coming-home-novartis) - [ ![Trees seen from below](/sites/novartis_com/files/styles/list_view_image_660_370/public/2021-09/view-of-the-sky-through-trees-in-a-forest.jpg.webp?itok=yz9AuV72 "Trees seen from below") Story Apr 13, 2026### New long term social impact and sustainability targets Novartis has announced new long-term [Social Impact & Sustainability (SI&S) targets](/investors/reporting-and-transparency-hub/social-impact-and-sustainability-targets "Social Impact and Sustainability targets") and goals, reinforcing our commitment to go beyond breakthroughs to maximize the impact of our medicines to support inclusive, resilient healthcare systems worldwide. ](/stories/new-long-term-social-impact-and-sustainability-targets) - [ ![a group of young people sitting on a stair outside in from of a building](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-03/inclusive-health-accelerators-group-photo.jpg.webp?itok=t0JcZAh1 "inclusive-health-accelerators-group-photo") Story Apr 09, 2026 Access to Healthcare### Working with communities to close gaps in heart disease and cancer care Our innovations matter only when they reach the people who need them. Yet millions live with heart disease or cancer without knowing it or have limited access to care – especially those in low-income, rural or other hard-to-reach communities. ](/stories/working-communities-close-gaps-heart-disease-and-cancer-care) - [ ![Victoria roller skates past a historic stone building](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-04/victoria-roller-skates-past-a-historic-stone-building.png.webp?itok=7wWxfqjB "Victoria roller skates past a historic stone building") Story Mar 30, 2026 Patient Perspectives### Managing Quality of Life with CML How shared decision-making can support living well from the start with chronic myeloid leukemia ](/stories/managing-quality-life-cml) - [ ![Modern technology learning center with interactive screens](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-03/modern-technology-learning-center-with-interactive-screens.png.webp?itok=wJF9MQh6 "Modern technology learning center with interactive screens") Story Mar 18, 2026 People and Culture### Building the Future: Novartis Innovation Lab - AI, Game Studio, XR & Emerging Tech The leaders behind the Novartis Innovation Lab share how they are leveraging emerging technologies to win for patients. ](/stories/building-future-novartis-innovation-lab-ai-game-studio-xr-emerging-tech) - [ ![Painted cellular image of breast cancer](/sites/novartis_com/files/styles/list_view_image_660_370/public/2026-03/painted-cellular-image-of-breast-cancer.png.webp?itok=sY_F8dGc "Painted cellular image of breast cancer") Story Mar 12, 2026 From Our Labs### Bringing proteins together to take cancer apart A Q&A with Jake Haling, Head of Oncology Drug Discovery in San Diego, on induced proximity and how it could open new paths to treat cancer. ](/stories/bringing-proteins-together-take-cancer-apart) [All news](/news/newsroom) --- ![Q2 2026 results](/sites/novartis_com/files/styles/cta_image/public/2026-04/q2-2026-thumbnail.jpg.webp?itok=88_suAgE "Q2 2026 results") ## Novartis Financial Results – Q2 2026 Novartis announces the company’s financial results for the second quarter and first half of 2026. [Learn more about the Q2 2026 results](/events/novartis-financial-results-q2-2026 "Learn more about the Q2 2026 results") ![High resolution picture of an artificial heart muscle from a research lab in Cambridge.](/sites/novartis_com/files/styles/cosmos_banner_half_image_large/public/2025-04/artificial-heart-muscle-from-research-lab-Cambridge.jpg.webp?itok=XRrjKmVO "High resolution picture of an artificial heart muscle from a research lab in Cambridge.") ## Live. Magazine Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company. [Learn more](https://live.novartis.com/ "Learn more") [ ![Doctor examining baby in Rwanda](/sites/novartis_com/files/styles/cards_50_50/public/2021-08/doctor-baby-rwanda.jpg.webp?itok=K9_uDBGp "Doctor examining baby in Rwanda") ### Stories Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible. ](https://www.novartis.com/stories) [ ![Medicine Exhibition at Novartis Pavillon](/sites/novartis_com/files/styles/cards_50_50/public/2024-10/medicine-exhibition-novartis-pavillon.jpg.webp?itok=OaqwkNjv "Medicine Exhibition at Novartis Pavillon") ### Events Keep informed about the latest Novartis events. From upcoming congresses and conferences to special forums, explore our event calendar for ongoing opportunities to connect and engage. ](/events) [ ![Office Cubicle](/sites/novartis_com/files/styles/cards_50_50/public/2021-10/contacts.jpg.webp?itok=J8WUv46L "Office Cubicle") ### Media contacts Find contacts at Novartis for media and journalist inquiries from the general and individual contacts. ](/contacts/media-contacts) [ ![Narrow photography of a man using a tablet](/sites/novartis_com/files/styles/cards_50_50/public/2021-08/digital-health-providing-opportunity-new.jpg.webp?itok=z8ekD1GW "Narrow photography of a man using a tablet") ### Media library Browse and download multimedia resources including images, videos, infographics and more. ](https://www.novartis.com/news/media-library) ![View of a desk with a phone and a monitor on it containing Novartis social media accounts](/sites/novartis_com/files/styles/cosmos_banner_half_image_large/public/2025-04/desk-newsroon-novartis-news-ig-li-in-body_0.jpg.webp?itok=yeadbQbX "View of a desk with a phone and a monitor on it containing Novartis social media accounts") ## #NovartisNews Tweets from the Media Relations team [Follow @NovartisNews](https://twitter.com/NovartisNews "Follow @NovartisNews") ![Novartis media relations on LinkedIn](/sites/novartis_com/files/styles/cta_image/public/2021-09/lp-newsroom-social-media.jpg.webp?itok=5jioT9fh "Novartis media relations on LinkedIn") ## Get the latest news and updates from Novartis directly to your inbox. [Subscribe](/news/stay-up-to-date "Subscribe")